Since acquired resistance ultimately limits the clinical efficacy of EGFR-TKI, it is imperative to explore further molecular mechanisms in order to overcome or defer the acquired resistance to EGFR-TKI in patients with NSCLC. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.